Search clinical trials for: Lorcaserin HCl

Total 2829 results

Beth Israel Deaconess Medical Center

Active, not recruiting

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

Obesity | Weight Loss

United States
Eisai Inc.

Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Chronic Weight Management

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

Obesity

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
Eisai Inc.

Available

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Epilepsies, Myoclonic | Drug Resistant Epilepsy
Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada
Johns Hopkins University

Terminated

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU (EMILI)

Sepsis | Muscle Weakness

United States
Scripps Whittier Diabetes Institute
Eisai Inc.

Completed

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

Obesity | Overweight | Weight Loss

United States
Eisai Inc.

Completed

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Pharmacokinetics in Obese Adolescents

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Renal Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Obesity

United States
University of Pennsylvania
Eisai Inc.

Completed

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Obesity

United States
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Healthy Participants

United States
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); New...

Terminated

Predictors of Lorcaserin-Induced Weight Loss

Overweight and Obesity

United States
Eisai Inc.

Completed

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Obesity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

Cannabis Use

United States
Eisai Inc.

Completed

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake (TULIP)

Obesity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Terminated

Lorcaserin for Cannabis Use Disorder

Cannabis Use Disorder

United States
New York State Psychiatric Institute

Completed

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

Cannabis Use Disorder

United States
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
National Institute on Drug Abuse (NIDA)

Completed

Lorcaserin in the Treatment of Cocaine Use Disorder

Cocaine-Related Disorders

United States
Midwest Biomedical Research Foundation

Unknown

Lorcaserin Intra Venous Cocaine Effects (LIVE)

Cocaine Use Disorders

United States
Kanion & Huawe Medicine Co.,Ltd

Terminated

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

Obesity

China
Eisai Inc.

Completed

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Obesity

United States
Eisai Inc.

Completed

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Obesity

United States
Eisai Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Obesity

United States
The Mind Research Network

Terminated

Mechanisms of Lorcaserin for Smoking Cessation

Smoking Cessation | Tobacco Use Disorder

United States
Arena Pharmaceuticals

Completed

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Smoking Cessation

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Completed

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

Opioid-Related Disorders | Opioid Dependence | Opioid Use | Opioid Abuse

United States
University of Virginia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

Type 1 Diabetes

United States
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Terminated

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

Opioid-Related Disorders | Cocaine-Related Disorders

United States
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization

Completed

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

Obesity | Cardiovascular Disease | Overweight | Type 2 Diabetes | High Cardiovascular Risk

United States, Canada, Poland, Australia, Mexico, New Zealand, Bahamas, Chile
Mayo Clinic

Completed

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Overweight | Obese

United States
Mclean Hospital

Active, not recruiting

Rebalancing the Serotonergic System in Cocaine Dependence

Cocaine Dependence

United States
Rabin Medical Center
Medtronic; GIF

Completed

An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Glycemic Control Using Hybrid-closed Loop vs. Advanced Hybrid Closed-loop in Young Subjects With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany, Israel
New York State Psychiatric Institute

Completed

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

Opioid-use Disorder

United States
Rabin Medical Center

Completed

Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2

Type 1 Diabetes

Israel
Universidad Complutense de Madrid

Completed

One- Versus Two-Stage Aesthetic Crown Lengthening

Patients in Need of Surgical CL in the Anterior Maxillary Sextant for Restorative Purposes
Southern California Institute for Research and...

Unknown

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

Weight Gain

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Completed

Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer

Breast Cancer

United States
Duke University
National Institute on Drug Abuse (NIDA)

Completed

Combination Nicotine Patch / Lorcaserin for Smoking Cessation (LorNic)

Nicotine Dependence

United States
Acologix, Inc.

Unknown

A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch) (AC120-8231)

Uremic Pruritus
Daiichi Sankyo, Inc.

Terminated

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
BioCryst Pharmaceuticals

Completed

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia
Daiichi Sankyo Co., Ltd.

Completed

Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

Type 2 Diabetes

Japan
Daiichi Sankyo Co., Ltd.

Completed

Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes (RAISE)

Type 2 Diabetes

China
The Mind Research Network

Terminated

Laboratory Screening of Lorcaserin for Alcohol Use Disorder

Tobacco Smoking | Alcohol Use Disorder

United States
Eli Lilly and Company

Completed

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

United States

3

Subscribe